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p53 regulates the mevalonate pathway in human
glioblastoma multiforme
C Laezza*,1,7, A D’Alessandro2,3,7, L Di Croce4, P Picardi2,3, E Ciaglia2,3, S Pisanti2,3, AM Malfitano2,3, M Comegna5,6, R Faraonio5,6,
P Gazzerro2,3 and M Bifulco*,2,3
The mevalonate (MVA) pathway is an important metabolic pathway implicated in multiple aspects of tumorigenesis. In this study,
we provided evidence that p53 induces the expression of a group of enzymes of the MVA pathway including 3′-hydroxy-3′-
methylglutaryl-coenzyme A reductase, MVA kinase, farnesyl diphosphate synthase and farnesyl diphosphate farnesyl transferase 1,
in the human glioblastoma multiforme cell line, U343 cells, and in normal human astrocytes, NHAs. Genetic and pharmacologic
perturbation of p53 directly influences the expression of these genes. Furthermore, p53 is recruited to the gene promoters in
designated p53-responsive elements, thereby increasing their transcription. Such effect was abolished by site-directed mutagenesis
in the p53-responsive element of promoter of the genes. These findings highlight another aspect of p53 functions unrelated to tumor
suppression and suggest p53 as a novel regulator of the MVA pathway providing insight into the role of this pathway in cancer
progression.
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The control of cellular metabolism is essential for a normal cell
behavior, and the role that aberrant cellular metabolism has in
cancer is becoming increasingly evident. During the course of
tumorigenesis, changes in metabolism enable cells to survive
and proliferate under adverse conditions that would directly
arrest or kill a normal cell.1 Recent work has highlighted
increased mevalonate (MVA) synthesis in malignant cells as
consequence of increased levels and catalytic efficiency of
3′-hydroxy-3′-methylglutaryl-CoA reductase (HMGCR), the
rate-limiting enzyme of cholesterol (CHO) biosynthesis that
catalyzes the formation of MVA 2 (Scheme 1). In addition, MVA
is required for a number of cellular processes including DNA
synthesis and proliferation.3 It is also the precursor of non-
sterol isoprenoids endowed with a variety of functions
including prenylation of growth-regulating proteins and
oncoproteins.4 Elevated MVA synthesis has been reported in
malignant breast cancer,5 lung,6 leukemia and lymphoma7
and hepatoma.8 Most recent results have shown that the
administration of exogenous MVA to xenograft-bearing mice
promoted tumor growth.9 Taken together, these results
suggest that MVA pathway may have an important role in
human malignancies. Indeed, recent transcriptional profiling
demonstrated that CHO and lipid metabolism are linked to
cellular transformation.10 However, it is not known whether the
alterations of MVA pathway contribute to cancer etiology or
whether its dysregulation occurs as a consequence of
transformation. Given the importance of metabolic reprogram-
ming in tumor development, it is not surprising that many
oncogenes and tumor-suppressor genes have been shown to
fine-tune these pathways.1,11 Their roles in carcinogenesis
have traditionally been attributed to the ability to regulate the
life and/or cell death.12 Anyway, evidence for an alternative
concept, which the primary functions of activated oncogenes
and inactivated tumor suppressors are to reprogram cellular
metabolism, has continued to build over the past years.
Among them, p53 seems to have an important role in
regulating several aspects of cellular metabolism that are
now being explored not only in cancer but in other diseases
and in development.13 The p53 tumor-suppressor protein is a
key factor in the cellular defense against carcinogenesis. It is a
transcription factor that responds to numerous extrinsic and
intrinsic challenges to the cell, including DNA damage,
oncogene activation and hypoxia, to promote a variety of
responses depending on the type, severity and persistence of
the stress.13 An emerging striking observation is that by
transcriptional activation and other means, p53 is able to
contribute to the regulation of several pathways as oxidative
phosphorylation, glutaminolysis, insulin sensitivity, nucleotide
biosynthesis, mitochondrial integrity, fatty acid oxidation,
antioxidant response, autophagy and mTOR signaling.14
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These evidences underscore the importance of the gene
regulation achieved by p53. In this study, we found that p53
regulates the expression levels of some enzymes of the MVA
metabolism in a human glioblastomamultiforme cell line and in
their normal astrocytic counterpart. It recruited the genes
promoters of these enzymes to activate their transcription.
These results reveal a novel role of p53 in the systemic
regulation of isoprenoid homeostasis.
Results
p53 induces the expression of MVA metabolism-related
genes in human glioblastoma cells. High or deregulated
activity of the MVA pathway has been demonstrated in
several different tumors.15,16 In order to study the activity of
this pathway in glioblastoma multiforme, we compared gene
expression profiles of six genes relative to MVA pathway,
including HMGCR, MVA kinase (MVK), farnesyl diphosphate
synthase (FDPS), farnesyl diphosphate farnesyl transferase
1 (FDFT1), Rab geranylgeranyl transferase 1α (RabGGTA)
and LDL receptor (LDLR) (Scheme 1) in U343 cells
expressing wild-type p53 and U251 cells with mutant p53
(R273H), carrying a mutation abolishing the DNA-binding
activity.17 Normal human astrocytes, NHAs, were used in
comparison. Quantitative real-time PCR (qRT-PCR) mea-
surements were conducted for mRNA levels of aforemen-
tioned genes (Supplementary Table 1). As shown in
Figure 1a, the obtained data revealed that they were
significantly upregulated at basal level in U343 cells expres-
sing wild-type p53 and downregulated in U251 cells with
mutant p53 (R273H), compared with NHA, a NHA cell line. In
this context, the mRNA levels of CDKN1A (p21waf) and
GADD45, known p53 target genes,18 paralleled with p53
activity. In order to verify if p53 activation induced the
expression of the genes involved in the MVA pathway, we
performed qRT-PCR measurement of the mentioned genes in
U343 cells treated with Nutlin 3a (Nut), which is known to
stabilize and activate p53.19 As shown in Figure 1c, we
observed that the expression levels of MVA pathway genes
were induced in Nutlin 3a-treated cells compared with
untreated cells. Furthermore, we evaluated by western blot
analysis (Figure 1b) the protein levels of the enzymes of the
MVA pathway and observed that they were overexpressed in
NHA cells and U343 cells untreated and treated with Nutlin
3a in comparison with U251 cells, thus confirming proper p53
activity in our experimental setup (Figure 1c). In parallel, in
order to demonstrate the transcriptional regulation of these
genes by p53, we transfected U343 cells with either an empty
vector (mock) or a vector encoding the mutant p53 (R273H)
(Figure 2a). The ectopic expression of a dominant-negative
mutant p53 (R273H) in U343 cells significantly attenuated the
mRNA levels of the six MVA pathway genes analyzed
(Figure 2a). The transfection efficiency has been confirmed
by western blot analysis (Figure 2a). To support the role of
p53 in transcriptional regulation of the enzymes of MVA
pathway, we knocked down p53 using a specific p53-siRNA.
We observed that the reduction of p53, as shown in western
blot in Figure 2f, turned down both the expression and protein
levels of the tested enzymes (Figures 2d and f). Then, to
corroborate our findings, we examined the expression of all
these genes following ectopic expression of wild-type p53 in
HEK293 cells. As shown in Figure 2c, the overexpression of
wild-type p53 in HEK293 cells, significantly induced the
mRNA levels of all genes compared with cells transfected
with empty vector (mock), instead the overexpression of
mutant p53 alone reduced the expression of analyzed genes.
The western blot in Figure 2e shows the transfection
efficiency. The role of p53 on these genes was confirmed,
at least in part, in U251 cells, after transfection with a vector
bearing wild-type p53 (Figure 2b). In order to further
generalize our findings, we tested the ability of p53 to
activate the MVA metabolism-related genes in human
adenocarcinoma breast cancer cell lines MCF7 with wild-
type p53 and MDA MB 231 with p53 mutant (R280T)17 and in
human adenocarcinoma colon cancer cell lines HCT116 with
wild-type p53 and SW620 with p53 mutant (R273H).17 In
accordance with human glioblastoma cells used in this study,
levels of six genes were increased in cell lines with wild-type
p53 compared with cell lines with mutant p53 (Supplementary
Data,Supplementary Figure S1).
p53 is recruited to p53-responsive elements in the
promoters of MVA pathway-related genes thereby
inducing their transcription. p53 induces transcription of
its primary target genes by a direct binding of PuPuPuC(AT)
(TA)GPyPyPy sequence presented in p53-responsive ele-
ment (p53RE) of DNA regulatory elements (promoters
and enhancers).20 Using Genomatix MatInspector,21 we
searched for putative p53REs in the promoters of the genes
relative to MVA pathway. These genomic regions consisted of
3-kb upstream and 2-kb downstream relative to transcription
start sites, whereas for FDFT1, MatInspector software
identified three sites located into intron in gene-coding
sequence. Each gene contained a putative p53RE in its
promoter (Supplementary Table 2). In order to confirm that
p53 binding to these sites, we performed chromatin
immunoprecipitation (ChIP) in U343 cells, U251 cells trans-
fected with an empty vector (mock) or a vector encoding the
wild-type p53 and in NHA cells, treated or not with etoposide
Scheme 1 Enzymes involved in MVA pathway
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(Eto) at 25 μM for 24 h. Then, we analyzed the amount of
DNA precipitated with an antibody against p53 or a control
antibody (IgG), using specific primers for the putative binding
site located in promoters in different areas relative to
transcriptional start site of each gene (Supplementary Table 3).
Genomic regions of HMGCR, MVK, FDPS and FDFT1 were
strongly enriched in the p53-immunoprecipitated chromatin,
indicating that p53 is recruited to the consensus sequence of
these genes (Figures 3a and b), whereas those of RabGGTA
and LDLR were only enriched in the NHAs (Figures 3c and
d). We validated the ChIP findings by analyzing the p53-
binding sites at the canonical p53 target CDKN1A (p21waf).
In order to distinguish between the endogenous and
transfected p53, we performed a CHIP assay in U251 cells
transfected with FLAG-p53 expression vector or with an
equivalent amount of empty vector, as shown in Figure 3f.
Then, we analyzed the amount of DNA immunoprecipitated
with anti-FLAG antibodies or a control antibody (IgG), using
specific primers for the putative binding site located in
promoters in different areas relative to the transcriptional
start site of each gene (Supplementary Table 3). Genomic
regions of HMGCR, MVK, FDPS and FDFT1 were strongly
enriched in the anti-FLAG-immunoprecipitated chromatin,
indicating that the transfected p53 effectively is recruited to
the consensus sequence of these genes (Figures 3e and g).
Next, we tested the functionality of the identified p53REs. To
this end, we cloned the DNA regions containing the putative
p53RE of HMGCR MVK, FDPS, FDFT1, RabGGTA and
LDLR into a luciferase reporter plasmid (Scheme 2;
Supplementary Table 2) and carried out a series of promoter
activity in U343 cells transfected with luciferase reporter
plasmids bearing promoter and intronic regions of enzymes
alone (Figure 4a) or in co-transfection with mutant p53
(R273H) (Figure 4b) and in U251 cells co-transfected with
wild-type p53 compared with cells co-transfected with mock
(Figure 4c) or reporter plasmids alone (Figure 4d). Luciferase
expression was significantly enhanced in a p53-dependent
manner in the constructs harboring the promoters of
HMGCR, MVK, FDPS, FDFT1 (Figures 4a and d), whereas
no luciferase activity in cell lines transfected with plasmids
bearing RabGGTA and LDLR promoters was observed (data
not shown). Moreover, in U343 cells, the same promoters
showed reduced luciferase activity when co-transfected with
the mutant p53 (Figure 4b). In order to confirm that the
p53REs in the promoters are responsible for the elevation in
luciferase activity, we mutated the genomic regions in the
p53-binding sites. We carried out two types of mutations:
(1) deletion of the region bearing the p53REs (Figure 4;
Supplementary Table 4) and (2) single mutations of core
nucleotides in the p53REs within the cloned fragment
(Scheme 2; Supplementary Table 4). Very interestingly, all
the mutants significantly reduced the p53-dependent induc-
tion of luciferase activity (Figures 4a and c). Taken together,
these findings suggest that p53 could bind to the specific
Figure 1 HMGR, MVK, FDPS, FDFT1, RabGGTA and LDLR expression in different cell lines. (a) qRT-PCR analyses in U343 cells with wild-type p53, U251 cells bearing a
mutant p53 (R273H) and NHA cells used as reference cell line for basal levels. CDKN1A and GADD45 genes served as a positive control. All the data represented mean± S.D. of
five independent experiments. Statistical analysis was conducted with one-way ANOVA and columns indicated with asterisks represent a significant difference in gene expression
levels (***P≤ 0.001; **P≤ 0.01; *P≤ 0.05) compared with NHA control cells. (b) Western blot analyses of protein levels of the MVA pathway enzymes and p21waf.
A representative actin was used for all samples as control. (c) qRT-PCR analysis of MVA pathway enzymes was conducted for U343 cells treated or not with Nut at 10 μM for 24 h.
Data are representative of three different experiments. A two-tailed t-test was conducted as statistical analysis. Columns indicated with asterisks represent significant increase
compared with unmarked columns (**P≤ 0.01; *P≤ 0.05)
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region of promoters of MVA metabolism-related genes
inducing their transcription.
p53 is recruited to the promoters of MVA pathway
enzymes independently from SREBPs proteins. The
physiologic regulation of MVA pathway enzymes requires
the sterol regulatory element-binding proteins. Recently,
Freed-Pastor et al.22 have described that the mutant p53 is
recruited at the promoters of sterol genes by SREBPs to
upregulate the expression of the sterol biosynthesis enzymes
in human breast cancer cells. In order to test the physiolo-
gical relevance of p53 into the transcriptional regulation of the
enzymes of MVA pathway irrespective of SREBP proteins,
we conducted qRT-PCR measurements of mRNA levels of
aforementioned genes, experiments of ChIP and luciferase
assays in U343 cells transfected with siRNA targeting
SREBP1 and SREBP2. qRT-PCR measurements after
depletion of SREBP1 and SREBP2 in U343 cells (as shown
in Figure 5d) substantially decreased the expression levels of
the enzymes but knockdown of p53 profoundly attenuated the
enzymes expression (Figure 5a). Moreover, we carried out a
quantitative ChIP analysis and observed that the ChiP signal
was consistently reduced upon depletion of p53 in compar-
ison with depletion of SREBP1 and SREBP2 (Figure 5b).
Next, the activity of promoters of the enzymes revealed that
the depletion of SREBP1 and SREBP2 slightly reduced the
activation of a luciferase reporter under the control of cloned
promoters of the enzymes in comparison with the depletion of
p53 (Figure 5c). Next, to evaluate the effects of knockdown of
SREBP1 and SREBP2 on the transcription of tested
enzymes, we transiently co-expressed FLAG-p53 with
specific siRNA of SREBP1 and SREBP2 in U251 cells (as
Figure 2 Analysis of mRNA levels of enzymes related to MVA pathway upon genetic perturbation of p53. qRT-PCR analysis of MVA pathway enzymes in (a) U343 cells
untransfected and transfected with empty vector control (mock) or with mutant (R273H) p53. Data were analyzed with a two-tailed t-test. Western blot showed p53 protein levels
following transfections with the plasmid constructs in U343 cells (ctr= untransfected cells; mock= cells transfected with empty vector; U343+p53(R273H)= cells transfected with
mutant p53). (b) U251 cells transfected with empty vector control or with vector containing wild-type p53 (pCMVp53). Western blot shows p53 protein levels following
transfections. (c) HEK293 cells transfected with control empty vector (mock), or with pCMVp53 alone, co-transfected with construct containing with mutant p53 or transfected with
(R273H) p53 alone. Western blot shows the transfection efficiency. Data are mean±S.D. of three independent experiments. One-way ANOVA analysis indicated a significant
difference in genes expression (**P≤ 0.001; *P≤ 0.05). (d) Knockdown of wt p53 from U343 cell line: cells transfected with siRNA p53 downregulated the expression and the
protein levels of enzymes of MVA pathway (f). A representative actin was used for all samples as loading control. (e) Western blot analyses shows the overexpression of p53 after
transfection in HEK293 cell line in the several experimental conditions. ***P≤ 0.001
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shown in Figure 6b) and carried out a ChiP assay (Figure 6a).
The chromatin region was immunoprecipitated with anti-
FLAG, thus indicating the p53 binding to promoter regions
of enzymes after depletion of SREBP1 and SREBP2
(Figure 6a). Luciferase assay of the enzymes revealed that
the knockdown of SREBP1 and SREBP2 causes a weak and
irrelevant reduction of the activity of promoter regions of
enzymes (Figure 6c).
p53 modulates CHO biosynthesis in glioblastoma cells.
As p53 regulates the expression of some enzymes of MVA
pathway, including HMGCR, the key regulatory enzyme of
isoprenoids synthesis, we measured the synthesis of CHO
product of MVA pathway in the human glioblastoma multi-
forme U343 and U251 cell lines and in NHA. In basal
condition, we observed an increase in the incorporation of
[14C]-acetate in CHO in U343 cells compared with U251 cells
Figure 3 ChIP assays in glioblastoma cells. Chromatin samples from (a) U343 cells, U251 cells and pCMVp53 transfected U251 cells were immunoprecipitated in the
presence of control rabbit IgG or with specific antibody anti-p53. p53 is immunoprecipitated along with p53REs of promoter of HMGR, MVK, FDPS, FDFT1. qRT-PCR analysis
was conducted using primers set specific for putative p53REs (Supplementary table 3). Obtained results were normalized to 1% input. (b) Representative agarose gels of PCR
products of ChIP assay using an antibody against p53 and anti-rabbit IgG as control of U343 cells, U251 cells and U251 transfected with p53wt. (c) qRT-PCR analysis of p53REs
co-immunoprecipitated with p53 in NHA cells untreated and treated with eto at 25 μM for 24 h. All the data are reported as mean±S.D. of two independent experiments. One-way
ANOVA was performed to indicate significant differences in genes expression. CDKN1A promoter was used as a positive control. (d) Representative agarose gels of PCR
products of ChIP assay using an antibody against p53 and anti-rabbit IgG as control of NHA and NHA treated with eto. (e) Chromatin samples from U251 transfected with FLAG-
p53 or with an equivalent amount of empty vector were immunoprecipitated with anti-mouse IgG, anti-FLAG or p53 antibodies as indicated. qRT-PCR analysis was conducted
using primers set specific for putative p53REs. (f) Western blot reports the amounts of FLAG-p53 and of p53 in one typical experiment. Actin was made as control of loading.
(g) Representative agarose of PCR products of ChIP assay using an antibody against FLAG and anti-rabbit IgG as control of U251 cells transfected with FLAG-p53 and equivalent
amount of empty vector. One-way ANOVA analysis indicated a significant difference in genes expression (*P≤ 0.05; **P≤ 0.001)
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and their normal astrocytic counterpart (Figure 7). In any
case, the presence of Lovastatin (Lov; 10 μM for 24 h), a
competitive inhibitor of HMGCR activity, inhibited the CHO
synthesis in U343, NHA and U251cell lines; moreover,
a transcriptional inhibitor of p53, cyclic pifithrin-alpha
(PT-α; 30 μM for 24 h) decreased the incorporation of
[14C]-acetate in CHO product in all cell lines (Figure 7).
Discussion
Malignant gliomas are highly dependent on the MVA pathway
for the synthesis of CHO and isoprenoid compounds
compared with their normal counterpart.23 This pathway is
highly regulated in untransformed cells, and loss of any one of
these regulatory mechanisms may contribute to dysregulation
of this critical pathway and ultimately drive tumorigenesis.24 In
this study, we analyzed the expression profiles of some
enzymes relative to this pathway in two different cell lines of
glioblastoma multiforme, U343 cells expressing a wild-type
p53 and U251 cells containing a mutant p53 (R273H) allele
lacking of transcriptional activity.17We observed that HMGCR,
MVK, FDPS, FDFT1, RabGGTA and LDLR are upregulated in
U343 cells and in NHAs compared with U251 cells bearing
mutant p53.We showed evidence that the expression of these
genes is positively regulated by p53, indeed the depletion of
p53 or the ectopic expression of mutant p53 in U343 cells
reduces the levels of the examined enzymes, whereas the
mRNA of CDKN1A, a known p53 target gene, is upregulated.
Probably in this case, the regulation is p53 independent but
others transcriptional factors25 may be involved. Taken
together, these findings show that p53 binds to a well-
defined p53-responsive element in the promoter region of
HMGCR, MVK, FDPS and FDFT1, and is able to induce their
transcription. Interestingly, p53 binds to the promoter regions
of the RabGGTA and LDLR in NHAs but not in U343 cells. In
the brain, the astrocytes are identified as producer of CHO
secreted by lipoproteins and supply CHO to the neurons via
LDLR.26 These results suggest the hypothesis that the
transformation of these cells from normal to malignant is
accompanied by a loss of p53 control of LDLR and RabGGTA,
the latter being already described as a p53 target gene in
human lymphoblastoid cell lines.27 How p53 discriminates
among the several binding sites is unclear, although recent
observations suggest that it may be due to aberrant DNA
methylation and associated to chromatin changes.28 In this
context, we observed that low levels of p53 in human
glioblastoma cells can enhance the mRNA levels of HMGCR
and of the other MVA pathway enzymes causing an increase
of the metabolic flux through the MVA pathway contributing to
the cell survival, according to the pro-survival roles of wild-type
p53.29 Recent work by Freed-Pastor et al.22 showed that
mutant p53 is recruited to genes that encode MVA pathway
enzymes by SREBPs proteins to upregulate their expression
in human breast cancer cells, contributing to the maintenance
of the malignant phenotype. Here, we revealed that p53 binds
to specific regions into the promoters of the genes relative to
MVA pathway independently from SREBP1 and SREBP2
proteins. Indeed, ChIP analysis of p53 on promoter of
enzymes after knockdown of SREBP1 and SREBP2 in U251
cell line with mutant p53 (R273H), revealed that p53 is
recruited at the promoters in any case and with the same
efficiency. Moreover, U251 cells express high level of SREBP1
and SREBP2, nevertheless they are unable to upregulate the
sterol biosynthesis genes. These results suggest that p53 by
itself can regulate the transcription of MVA pathway enzymes,
however, we observed that in U343 cells the depletion of
SREBP1 and SREBP2 slightly reduced the binding of p53 to
the promoters suggesting that the transcriptional regulation by
p53 may occur through several transcriptional co-regulators
that have an integral role in the physiological functions of p53.
The upregulation of MVA pathway in U343 cells caused a
greater elevation in the de novo synthesis of CHO compared
with U251 cells and astrocytes. In U251 cells, we observed a
40% decrease in total cell CHO. Furthermore, the treatment
with cyclic PT-α, an inhibitor of the transcriptional activity of
p53, inhibited the [14C]-acetate incorporation in CHO in U343
cells suggesting a correlation between p53 and CHO pathway.
The results shown here suggest that in U343 cells, p53 could
be the major regulator of the MVA pathway allowing the
elevation of CHO metabolism essential for cellular survival.
The hypothesis currently under investigation is that the
upregulation of CHO metabolism could then drive tumorigen-
esis. Recent evidence have described that, although p53 is a
tumor suppressor, some of its downstream targets do not have
a tumor-suppressive function. The research of the pro-survival
function of p53 is essential for cancer therapy 30 because the
identification of novel treatments targeting the pro-survival
function of p53 could direct the cancer cells toward
Scheme 2 Promoter regions containing p53REs cloned in pGL3 luciferase
reporter vector. p53REs positive to ChIP assays were cloned and integrated in a
pGL3 luciferase reporter vector to evaluate the link between these potential
promoter regions and p53 transcriptional activity. Regions cloned from HMGCR,
MVK, FDPS, FDFT1 genes were also deleted and mutated in p53RE and
subsequently tested for luciferase transcription ability
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apoptosis, thus allowing the acquisition of optimal efficacy for
chemotherapy. We observed that U251 cells bearing mutant
p53, although unable to upregulate the sterol biosynthesis
genes, showed a high rate of endogenous CHO synthesis
allowing the elevated rate of cell proliferation, to understand
this mechanisms are needed for further studies. We believe
that the reduction of sterol biosynthesis genes levels and, as
consequence, a reduced amount of intracellular CHO make
this cell type particularly sensitive to the inhibition of this
pathway.31 Indeed, the treatment with Lov reduced consider-
ably the amount of free CHO (Figure 7). In addition, most of
glioma cells with wild-type p53 exhibit a high resistance to
cytotoxic treatments used in clinical practice compared with
glioma cells with transcriptionally inactive mutant p53.32
It appears that p53 activities associated with DNA repair
contribute to the overall survival potential and drug resis-
tance. Supporting the notion, there is evidence that
chemoresistance mediated by p53 in glioma relies at least
in part on the ability of p53 to activate the transcription of DNA
repair genes,33 and of genes whose products directly
contribute to drug resistance of glioma to temozolomide
such as MGMT (O6-methylguanine-DNAmethyltransferase),
an enzyme that removes methyl and chloroethyl groups from
the O6-position of guanine.34 Furthermore, the effects of p53
on drug resistance and the survival potential seen in different
types of cancer cells, could be due to the activation of CHO
pathway that, in order to support cell survival, may modulate
resistance to a variety of anticancer drugs, within a functional
phenotype termed multidrug resistance (MDR). The plasma
membranes of MDR+ tumor cells are rich in fact, in CHO
that assists the activity of Pglycoprotein (Pgp), an integral
membrane transporter chemotherapy drugs. Another
hallmark of MDR+ tumor cells is the increased prenylation
and activity of GTP-binding proteins, which are also
dependent on the rate of the MVA pathway activity.35 In
summary, our results show that p53 is an essential
transcription factor for the regulation of MVA pathway,
and further studies will be necessary to determine the
mechanism by which p53 regulates the MVA pathway
enzymes. A better understanding of how p53 coordinates
metabolic adaptation will facilitate the identification of novel
therapeutic targets and will also illuminate the wider role of
p53 in human biology.
Materials and Methods
Cell cultures and reagents. NHAs are normal human cells derived from
human brain tissue and were cultured in AGM BulletKit medium (Lonza,
Portsmouth, NH, USA), these cells were used as normal control system.
Figure 4 Luciferase reporter assays in glioblastoma cells. (a) U343 cells were transiently transfected with three different pGL3 plasmids wt: containing the promoter regions
containing p53RE (wild type) from HMGCR, MVK, FDPS and FDFT1 gene sequences, Δp53RE: the constructs with deleted-cloned sequences of the mentioned genes
(Δp53RE) and mut: the constructs containing promoter regions with single mutation of p53 of HMGCR, MVK, FDPS and FDFT1 genes (mut). (b) U343 cells were co-transfected
with mut (R273H) p53 plasmid and with constructs containing promoter regions. (c) wt p53-transfected U251 cells were co-transfected with constructs containing wt and mutated
promoter regions of enzymes of MVA pathway. (d) U251 cells were transfected with promoter regions–constructs of MVA enzymes. Results were normalized for β-galactosidase
activity and compared with results obtained in cells transfected with empty vector (mock). Data represent mean±S.D. of three independent experiments and statistical analysis
was performed with one-way ANOVA, *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001
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Glioblastoma multiforme cell lines U343 and U251 cells (CLS, Berlin, Germany)
were maintained in EMEM, supplemented with 10% fetal bovine serum (FBS), 2 mM
L-glutamine, 0.1 mM non-essential amino acids, 1.0 mM sodium-pyruvate. Human
embryonic kidney 293 cells (HEK293) were maintained in DMEM supplemented
with 10% FBS. All cell lines were cultured at 37 °C in 5% CO2 controlled
atmosphere. Reagents Eto, PT-α and Nut were purchased from Sigma-Aldrich S.r.l.
(Milan, Italy). Cells were treated with Eto 25 μM for 24 h, PT-α was used at a
concentration of 30 μM for 24 h, whereas Nut was administered at 10 μM for 24 h.
Lov, a gift from Dr. AW Alberts of the Merck, Sharp and Dohme Institute (Kenilworth,
NJ, USA), was used at 10 μM for 24 h of treatment. siRNA targeting SREBP1 (h)
(sc36557) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). siRNA
p53 (106141), SREBP2 (s27) and Lipofectamine RNAiMAX reagent were from
Invitrogen (Carlsbad, CA, USA).
Immunoblotting. Cells were harvested after 24-h treatment, washed twice with
phosphate-buffered saline (PBS) and resuspended in lysis buffer with protease
inhibitors (Hepes 50 mM, NaCl 150 mM, EDTA 50 mM, NaF 100 mM, Na
ortovanadate 2 mM, glycerol, Na4P2O7 10 mM, 10% Triton pH 7.5, all compounds
were from Sigma, Milan, Italy). Protein concentration was determined by Bio-Rad
Protein Assay (Bio-Rad, Berkeley, CA, USA), 50 μg of proteins were resuspended in
Laemmli sample buffer and loaded onto a SDS–PAGE. Samples were resolved
under constant voltage (40 mA) and transferred onto nitrocellulose blot (100 V).
Figure 5 (a) qRT-PCR of enzymes related to MVA pathway, (b) ChIP assays and (c) luciferase reporter analysis of U343 cells after knockdown of SREBP1, SREBP2 and p53.
U343 cells were treated with a control siRNA or siRNA directed against SREBP1, SREBP2 and p53. (d) Immunoblot shows knockdown of SREBP1 and SREBP2 (see also
Figure 3f for the depletion of p53). Actin was made as control of loading. Data represent mean± S.D. of three independent experiments and statistical analysis was performed
with one-way ANOVA, *P≤ 0.05; **P≤ 0.01
Figure 6 (a) ChIP assays and (c) Luciferase reporter analysis of U251 cells after knockdown of SREBP1 and SREBP2. U251 cells were co-transfected with FLAG-p53 and
control siRNA or siRNA directed against SREBP1 and SREBP2. (b) Immunoblot shows knockdown of SREBP1 and SREBP2. Actin was made as control of loading. Data
represent mean± S.D. of three independent experiments and statistical analysis was performed with one-way ANOVA, *P≤ 0.05; **P≤ 0.01
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Blots were blocked in PBS containing 0.1% Tween 20 and 5% no fat dry milk for 1 h
at room temperature. Filters were probed overnight with primary specific antibodies
at 4 °C: mouse anti-p53 (sc-126), rabbit anti-p21waf (sc-756), rabbit anti-HMGR
(sc-271595), rabbit anti-MVK (sc-366285), rabbit anti-FDFT1 (sc-99145), rabbit
anti-RabGGTA (sc-133617), mouse anti-LDL (sc-18823), anti-mouse SREBP1
(sc365513) and anti-SREBP2 (sc-5603) were from Santa Cruz Biotechnology, rabbit
anti-FDPS (ab-38854), anti-FLAG was from Sigma. Immunodetection of specific
proteins was carried out with horseradish peroxidase-conjugated goat anti-mouse or
anti-rabbit IgG (Bio-Rad) for 1 h at room temperature and visualized using the
Enhanced Chemiluminescence (ECL) system (Amersham, Little Chalfont, Buck-
inghamshire, UK), images were scanned with Bio-Rad’s Chemidoc system.
Quantitative real-time PCR. Total RNA was isolated using the NucleoSpin
RNA II kit (Macherey-Nagel, Mountain View, CA, USA). Complementary DNA
(cDNA) was transcribed using SuperScript II Reverse Transcriptase (Invitrogen),
starting from 1 μg of high pure RNA. MVA genes expression profiles were evaluated
with specific primer sets (Supplementary Table 1) and using SsoFast EvaGreen
reagents (Bio-Rad), b2-microglobulin was used as housekeeping gene. qRT-PCR
protocol was: a pre-heating step for 3 min at 95 °C, 40 cycles at 95 °C for 10 s and
60° for 30 s and last end-step at 65 °C for 10 s. Results were analyzed with
2-ddCt method.36
Plasmid constructs. Human p53 expression plasmids pCMV-p53wt and
pCMV-p53 R273H plasmid was purchased by Addgene (#16439, Cambridge, MA,
USA),37 pcDNA3 flag p53FLAGp53 was purchased by Addgene (plasmid
#10838).38 MVA genes’ promoter constructs containing p53REs were amplified
with the high fidelity Taq AccuPrime Pfx DNA Polymerase (Invitrogen). Protocol was:
2 min at 95 °C followed by 28 cycles 15 s at 95 °C, 30 s at 55–58 °C and 1 min at
70 °C using primer sets showed in Supplementary Table 2 and 4. Products were
digested as KpnI/HindIII fragments and ligated into the pGL3-Basic Vector firefly-
luciferase reporter-gene vector (Promega, Madison, WI, USA). Restriction enzymes
and the T4 DNA ligase were from New England BioLabs (Ipswich, MA, USA).
Promoter constructs with deletion of specific p53REs were assembled using same
cloning protocol and using primer sets described in Supplementary Table 4.
Promoter constructs carrying mutations in the p53REs were obtained by site-
directed mutagenesis kit, QuikChange II-E Site-Directed Mutagenesis Kit (from
Agilent Technologies, Santa Clara, CA, USA) and mutagenic primers
(Supplementary Table 4). All constructs confirmed to be the sequence of interest
by sequencing. Cell transfection-U251 cells at 90% of confluence were transfected
with 5 μg of pCMVp53 plasmid using Lipofectamine 2000 (DNA/Lipofectamine ratio
was 1/2.5) and were harvested 48 h after transfection. U343 cells were transfected
with 5 μg of mut(R273H)p53 plasmid, whereas HEK293 cells were transfected with
5 μg of pCMVp53 or co-transfected with a total amount of 6 μg DNA (pCMVp53
+mut(R273H)p53 plasmids). Six hours after transfection, incubation medium was
replaced with fresh and FBS supplemented medium. Control cells were transfected
with empty vector (mock).
Chromatine immunoprecipitation. ChIP experiments were carried out
with MAGnify Chromatin Immunoprecipitation System (Invitrogen) using a minimum
of 6x106 cells. U251 cells at 90% of confluence were transfected with 2 μg of
pCMVp53 plasmid using Lipofectamine 2000 and were harvested 48 h after
transfection. Cells were harvested and washed with PBS, then chromatin/proteins
complexes were cross-linked with 1% of formaldehyde for 10 min, then cells were
lysed and DNA were sonicated with BRANSON digital sonifier 251 (Medford, NY,
USA), to have DNA fragments of 500–1000 base pairs. An aliquot of sheared
chromatin was stored and processed as DNA input control, whereas 300 μl of
sonicated chromatin solution were incubated overnight at 4 °C with 5 μl of rabbit
anti-human p53 polyclonal antibody (Life Technology, Carlsbad, CA, USA). As
negative control (non-IP), a chromatin fraction was incubated in parallel with rabbit
IgG. All antibodies were coupled to magnetic beads (Dynabeads, Waltham, MA,
USA). Finally, DNA was de-cross-linked and purified using DNA Purification
Magnetic Beads. Isolated DNA was subjected to qRT-PCR analysis using specific
primes (Supplementary Table 3), results are shown as chromatin enrichment to
input and are adjusted for their respective non-IP.
Reporter gene assays. Cells were plated in 48-well plates in triplicates
(5 × 104 cells per well) and 24 h later were transfected using Lipofectamine
2000 (Invitrogen) with 1 μg per well of pGL3 plasmids harboring the promoters of
the mentioned genes (Supplementary Table 2), and or 1 μg per well of pCMV-p53wt
a or empty vector (mock). To normalize transfection efficiency for reporter
vector assays, cells were co-transfected with b-galactosidase (b-Gal) plasmid
(500 ng per well) (Promega). Forty-eight hours after transfection, cells were
harvested and washed with PBS and then lysed with the reporter lysis buffer
(Promega). Luciferase activities in cell lysates were measured with the Luciferase
System Assay (Promega) and read at luminometer and normalized to control
b-Gal activity.
[14C]- acetate uptake. Actively growing, subconfluent cells were incubated
with Lov (10 μM for 24 h) and PT-α (30 μM for 24 h). Afterward, cells were incubated
with 20 μl of 2-14C-acetate([14C]- acetate) (Specific activity: 59mCi/mM from Perkin
Elmer, Waltham, MA, USA) for 12 h. Cells were washed and harvested with cold
PBS, resuspended in 500 μl of isopropanol and sonicated. After centrifugation,
supernatants were dried and dissolved in 50 μl of chloroform, whereas pellets
were solubilized in 500 μl di 0.1 M NaOH for protein assay. In all, 10 μl of each
sample were loaded on Thin Layer Cromatography – Silica gel-60G (Millipore,
Billerica, MA, USA) in presence of 1,2-3H(N)cholesterol standard (Specific
activity 60.0 Ci/mM from NEN products – DuPont, Boston, MA, USA) and
developed in hexane/diethylether/acetic acid (70 : 30 : 1) used as solvent
system.39 Membranes were exposed to X-ray film and film developed, spots
were quantified by densitometry using a digital imaging system (Image Lab
software, Berkeley, CA, USA).
Statistical analysis. Data are reported as mean± S.D. of three independent
experiments. When comparing two means, statistical significance (P≤ 0.05) was
assessed by Student’s two-tailed t-test. When comparing more than two
experimental groups, we used one-way ANOVA statistical analysis (*P≤ 0.05;
**P≤ 0.01; ***P≤ 0.001).
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Figure 7 [14C]-acetate incorporation in neo-synthesized CHO. Chromatogram of
non-saponifiable lipids from cells radiolabeled during a 14-h period following
treatment. U343 and U251 cells were incubated with Lov (10 μM for 24 h) and cyclic
PT-α (30 μM for 24 h). CHO bands are indicated with an arrow and the graphic
represents densitometric analysis of two independent experiments. Statistical
analysis was performed with one-way ANOVA *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001
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